Form 4: Tandem Diabetes Care Officer's Stock Transactions
Insider Transaction Report
Tandem Diabetes Care's EVP & Chief Legal Officer reported routine stock acquisitions and dispositions related to Restricted Stock Unit vesting.
Summary
- Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions involving the company's common stock.
- On August 15, 2025, Hansen acquired a total of 3,065 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
- Concurrently, 1,098 shares were disposed of at a price of $10.82 per share to satisfy tax withholding requirements related to the RSU vesting.
- No shares were sold by the reporting person; the dispositions were solely for tax purposes.
- Following these transactions, Hansen directly owns 18,709 shares of common stock and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
- Remaining unvested derivative securities include 1,061, 4,311, and 7,677 Restricted Stock Units from awards on February 15, 2022, May 25, 2023, and May 23, 2024, respectively.
Sentiment
Score: 5
Explanation: The filing is neutral as it reports routine, pre-planned transactions related to executive compensation (RSU vesting and tax withholding) and does not indicate any discretionary buying or selling activity.
Positives
- The transactions represent the vesting of previously awarded Restricted Stock Units, indicating the fulfillment of long-term incentive compensation plans.
- The disposition of shares was solely for tax withholding, not an open-market sale, which is a neutral event regarding management's confidence in the company.
Negatives
- No negative information was disclosed in this routine Form 4 filing.
Risks
- No specific risks were detailed in this Form 4 filing, which primarily reports insider transactions.
Future Outlook
The filing indicates ongoing vesting schedules for Restricted Stock Units, with future vesting dates extending into quarterly installments following initial vesting milestones on May 15, 2024, and May 15, 2025.
Industry Context
This filing is a routine insider transaction report, common across all industries for publicly traded companies, reflecting standard executive compensation practices involving equity awards like Restricted Stock Units. It does not provide specific insights into broader industry trends in diabetes care.
Comparison to Industry Standards
- The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across the healthcare and technology sectors, aligning executive incentives with long-term shareholder value.
- The withholding of shares to cover tax obligations upon RSU vesting is a standard, non-discretionary practice, consistent with compensation structures at comparable medical device companies such as Dexcom (DXCM) or Insulet Corporation (PODD).
Related Party Transactions
- Securities are held indirectly by the Shannon M. Hansen Trust dated July 8, 2003, of which Shannon M. Hansen is the Trustee.
Stakeholder Impact
- Shareholders: The filing reflects standard executive compensation practices, which can align management's interests with shareholder value over the long term through equity ownership.
- Employees: The RSU vesting demonstrates the company's commitment to its long-term incentive plans for key executives, which can be a positive signal for employee retention and motivation.
- Creditors: No direct impact on creditors as the filing pertains to equity compensation and does not involve debt or liquidity changes.
Next Steps
- Future vesting of remaining Restricted Stock Units will occur in twelve equal quarterly installments following February 15, 2023, for the 2022 award.
- Future vesting of remaining Restricted Stock Units will occur in eight equal quarterly installments following May 15, 2024, for the 2023 award.
- Future vesting of remaining Restricted Stock Units will occur in eight equal quarterly installments following May 15, 2025, for the 2024 award.
Key Dates
| Date | Description |
|---|---|
| 2003-07-08 | Date of the Shannon M. Hansen Trust. |
| 2022-02-15 | Date of RSU award under the 2013 Stock Incentive Plan, with 25% vesting on 2/15/2023 and remaining in 12 equal quarterly installments. |
| 2023-02-15 | First vesting date for RSUs awarded on February 15, 2022. |
| 2023-05-25 | Date of RSU award under the 2023 Long-Term Incentive Plan. |
| 2024-05-15 | First vesting date for RSUs awarded on May 25, 2023, with 33% vesting and remaining in 8 equal quarterly installments. |
| 2024-05-23 | Date of RSU award under the 2023 Long-Term Incentive Plan. |
| 2025-05-15 | First vesting date for RSUs awarded on May 23, 2024, with 33% vesting and remaining in 8 equal quarterly installments. |
| 2025-08-15 | Date of reported stock transactions (RSU vesting and tax withholding). |
| 2025-08-19 | Date the Form 4 filing was signed. |
Keywords
Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transactions, Corporate Governance, Diabetes Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.